|
|
(HealthNewsDigest.com) – Amherst, NH – Driven primarily by strong demand for engineered antibodies for treating a growing list of cancers, commercial protein drugs – a group that includes recombinant mAbs, cytokines and related immune modulators, growth factors, enzymes, and hormones – are forecast to grow at a 9.7% CAGR over the next four years, reaching $103 billion by 2014, according to the latest estimates from Greystone Research Associates.
“Growth in this sector will come from increasing demand for oncology treatments and the continued strong performance of biological drugs for treating autoimmune diseases,” explains George Perros, Greystone Research Managing Director. But performance across all therapeutic segments will be uneven. “While still a young industry by pharmaceutical standards, several protein drug market segments are beginning to show signs of maturing, creating a new set of challenges for pharmaceutical and biotech decision makers.”
The impact on key protein drug therapeutic segments will vary. Oncology, where therapeutic proteins have been averaging solid double-digit growth over the past several years, will remain strong as existing antibody drugs gain approval for expanded indications and new proteins enter the market. Anti-inflammatory immune factor drugs will also remain strong, with growth rates dropping off only slightly by the middle of the new decade. Other segments, including proteins for treating growth deficiency and for chronic viral infections, as well as hematopoietics indicated for chemotherapy induced anemia, will not fare as well due to a number of demographic, socioeconomic and competitive factors.
Greystone’s Therapeutic Proteins to 2014 (http://greystoneassociates.org/Reports/Drug_Delivery/DTP/Therapeutic_Proteins_Markets_&_Forecasts.htm) study analyzes commercial protein drugs and development-stage candidates, examines key demand and technology factors influencing market demand and shaping growth prospects, and provides forecasts by segment to 2014.
More information is available at www.greystoneassociates.org
About Greystone
Greystone Research Associates is a medical technology management consulting firm. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and achieve their financial targets.
Subscribe to our FREE Ezine and receive current Health News, be eligible for discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
For advertising/promotion, email: [email protected] Or call toll free: 877- 634-9180